dolutegravir

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:

• Guideline recommendations for selecting a new ART regimen
• Options for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistance
• Data from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIV

Presenter:

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

To download the slides:
https://bit.ly/3OcqxIE

To view the full online program:
https://bit.ly/3ZjSFhg

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:

• The definitions of virologic blips, low-level viremia, and virologic failure on ART
• The infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real world
• The potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factors
• The impact of adherence on viral suppression with BIC- and DTG-based ART
• Drug-drug interactions as a reason for failure of first-line INSTI-based ART
• What to do if someone is experiencing virologic failure requiring an ART change
• The use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experience
• The impact of high HIV-1 RNA on ART effectiveness
• The impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ART
• Strategies to encourage and measure patient adherence to ART 

Presenters

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

Cristina Mussini, MD
Professor
Department of Infectious Diseases
University of Modena and 
Reggio Emilia
Modena, Italy

Link to full program: https://bit.ly/3HPu4Lk

In this episode, Renslow Sherer, MD, discusses managing a first ART failure in the setting of COVID-19, including:

• Guideline recommendations for resistance testing
• Guideline recommendations for selecting a new ART regimen
• Data on retained efficacy of NRTIs in second-line regimens in the EARNEST and NADIA studies
• Consideration of drug‒drug interactions between ART and COVID-19 treatment

Presenter: 
Renslow Sherer, MD
Director 
International HIV Training Center 
Professor of Medicine 
Section of Infectious Diseases and Global Health 
Department of Medicine 
University of Chicago 
Chicago, Illinois 

To download the slides: https://bit.ly/3OcqxIE 

To view the full online program: https://bit.ly/3ZjSFhg

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:

• Hyperlipidemia and cardiovascular disease risk among people living with HIV
• Recommendations for lipid screening for people living with HIV
• Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
• How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
  • Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
  • Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
• How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
• How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database

Maunank Shah, MD, PhD 
Associate Professor 
Infectious Diseases 
Johns Hopkins University 
Baltimore, Maryland 

Link to full program: bit.ly/3pwaH2Y

In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:

• Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines 
• Data for weight gain after ART initiation with different ARV classes and drugs
• Weight gain disparities by race and gender after ART initiation
• Data from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART 
• The impact of INSTIs on CV events in the Swiss HIV Cohort study 
• Recommendations for ART and contraception for PWH of childbearing potential 
• Drug–drug interactions between first-line ART and contraceptive options 
• Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH 

Marta Boffito, MD, PhD, FRCP 
Consultant Physician 
Clinical Director, HIV, Sexual and Gender Health, Dermatology 
Chelsea and Westminster Hospital NHS Foundation Trust 
Imperial College London 
London, United Kingdom 

Michelle Cespedes, MD, MS 
Professor of Medicine 
Division of Infectious Disease 
Department of Medicine 
Icahn School of Medicine at 
Mount Sinai 
New York, New York 

Link to full program: bit.ly/3HPu4Lk

In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:

• How to input patient specific factors into the HIV-ASSIST tool
• Discussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancy
• An explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequency
• Guidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporated
• How to use the HIV-ASSIST output to guide regimen selection in pregnancy
• Use of the HIV-ASSIST tool in shared decision-making and patient counseling

Sonya Krishnan, MD, MHS
Assistant Professor
Division of Infectious Diseases
Johns Hopkins University
Baltimore, Maryland

Link to full program: 
bit.ly/3pwaH2Y

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for patients experiencing weight gain on antiretroviral therapy, including:

• Commonly implicated antiretroviral therapy regimens and patient populations

• Guideline recommendations for management of weight gain

Presenter:

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

To download the slides: 
bit.ly/3odUA9C

To view the full online program: 
bit.ly/3ZjSFhg

In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:

• Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)
• Optimizing the use of the Antiretroviral Pregnancy Registry
• Addressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)

Faculty: 
Jill Blumenthal, MD, MAS
Associate Professor of Medicine
Infectious Diseases and Global Public Health 
University of California, San Diego
San Diego, California

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases 
Department of Medicine  
Perelman School of Medicine at the University of Pennsylvania 
Philadelphia, Pennsylvania

Link to full program:
http://bit.ly/3PM3nYe

Link to downloadable slides: 
http://bit.ly/3WgYycz

 In this episode, 2 Australian HIV experts share their thoughts on some of the most important HIV insights gained during the past year in the context of HIV care in Australia.

Specifically, the faculty discuss the continued dominance of second-generation INSTI-based regimens as mainstay HIV therapy in Australia, including in both 2-drug and 3-drug oral regimens; the emergence of 2-drug long-acting injectable therapy as a switch strategy; key aspects of successfully expanded oral PrEP programs in the region; the potential role of long-acting injectable PrEP; and key new advances in HIV cure research.  

Presenters:

Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne  
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital  
Melbourne, Australia

Don Smith, MD
Conjoint Professor
School of Population Medicine
University of New South Wales
Senior Staff Specialist
Albion Centre
South Eastern Sydney Local Health Network
Sydney, Australia

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.  

Link to full program:
http://bit.ly/3YD8T4E

In this episode, 2 European HIV experts share their thoughts on some of the most important new antiretroviral therapy insights from HIV research over the past year.

Specifically, the faculty discuss findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, how 2-drug options fit into rapid start strategies, and other new and emerging innovations in HIV treatment, including the availability of lenacapavir for multidrug-resistant HIV treatment and resumption of islatravir clinical development.

Presenters:

Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Alexandra Calmy, MD, FMH, PhD
HIV/AIDS Unit Director
Infectious Diseases Division
Geneva University Hospitals
University of Geneva
Geneva, Switzerland

Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.

Link to full program:
http://bit.ly/3Hz0jNa

In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:

• Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancy
• What data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelines
• Available data on newer ARVs in the ARV pregnancy registry
• Pharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancy
• Recommendations for 2-drug ART regimens in pregnancy
• What to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelines

Annette Haberl, MD
Physician
Head of HIV and Women
HIVCENTER Frankfurt
Department of Infectious Disease
Hospital of the Johann Wolfgang Goethe University
Frankfurt, Germany

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program:
https://bit.ly/3HPu4Lk

In this episode, Winnie Sseruma and Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, discuss some of the barriers to genuinely patient-centered HIV care in Africa and offer calls to action for healthcare professionals for responding to patient preferences.

They discuss the efforts to improve patient-centered HIV care in the foundations and organizations for which they work. They also address issues related to stigma around HIV and complacency and lack of visibility for HIV.

You will then hear them talk through differentiated service delivery in South Africa and Mozambique as models for other parts of Africa. They focus on HIV prevention and some of the difficulties of reaching certain populations to better communicate effective prevention practices.

They end with a discussion about the importance of documenting the experiences and stories of people living with HIV.

Winnie Sseruma
International Development Consultant 
London, United Kingdom

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Link to full program:
https://bit.ly/3Fxsfkz

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:

• Prevention strategies
• Oral therapies
• LA therapies
• Cure
• COVID-19 in PWH

Faculty
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Follow along with the slides at
bit.ly/3SLuhBq

In this episode, Chloe Orkin, MBChB, FRCP, MD​, discusses strategies for successful antiretroviral therapy (ART) initiation. Her overview includes:

• Recommendations for rapid ART
• First-line ART regimens for treatment-naive people with HIV
• IMEA 055 FAST study
• STAT study
• DIAMOND study
• Antiretroviral resistance mutations
• Patient perspectives on the importance of rapid ART initiation

Presenter:

Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London​
Consultant Physician​
Lead for HIV Research
Barts Health NHS Trust​
The Royal London Hospital​
London, United Kingdom​

Panelists:

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​
Director
Desmond Tutu HIV Centre​
Past President
International AIDS Society​
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa​

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​
Chief and Director
VHS Infectious Diseases Medical Centre​
Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​
Voluntary Health Services​
Chennai, India

Babafemi Taiwo, MBBS​
Gene Stollerman Professor of Medicine​
Chief, Division of Infectious Diseases​
Northwestern University
Feinberg School of Medicine​
Chicago, Illinois

Content based on an online CME program supported by an independent educational grant from Gilead Sciences.

Follow along with the slides: 
https://bit.ly/3dSNoum

Link to full program:
https://bit.ly/3AE2AV1

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients.

Listen as she gives perspectives on:

• Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmission
• DHHS guideline–recommended ART regimens for children
• The ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescents
• Data for the use of the fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide in children and adolescents
• Key ART and management considerations for adolescents and young adults with HIV

Presenter:

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV  
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein  
College of Medicine
Bronx, New York  

Follow along with the slides at:
https://bit.ly/3wMur29

Link to full program:
https://bit.ly/3fOl0XX

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:

• Prevention strategies
• LA therapies
• Second-line therapies
• The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapy
• The NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
• Comorbidities and cure
• ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
• IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant

Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases Clinical Trials Unit
University of North Carolina at Chapel Hill

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at:
https://bit.ly/3CItz0Z

Link to full program:
https://bit.ly/3tSpdAx

In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies of LA CAB plus RPV and the CUSTOMIZE study.

Presenters:

Fidelia Bernice, PharmD
Clinical Pharmacy Specialist
Infectious Diseases
Department of Pharmacy
University of Maryland Medical Center
Baltimore, Maryland

Aadia I. Rana, MD
Associate Professor of Medicine
Division of Infectious Diseases
University of Alabama at Birmingham
1917 Clinic
Birmingham, Alabama

Content based on a CME program supported by independent educational grants fromJanssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.

Link to full program:
https://bit.ly/3ydMtcL

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.

Listen as he gives his perspectives on:

• Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
• The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
• Real-world experience with switching to DTG/RPV from the OPERA study
• The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
• The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen

Presenter:
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Follow along with the slides at:
https://bit.ly/3n0Z8wU

See the entire program at:
https://bit.ly/2TXTYWx

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on maternal weight gain associated with ART use in pregnancy.

Listen as she gives her perspectives on:

• IMPAACT 2010 data on maternal weight gain with DTG + FTC/TAF vs DTG + FTC/TDF vs EFV/FTC/TDF
• SMARTT study data on gestational weight gain by ART class
• Tsepamo Surveillance study data on maternal weight and birth outcomes among women receiving ART, as well as weight outcomes with DTG vs EFV
• DHHS Perinatal Guideline recommendations on dolutegravir and maternal weight gain

Presenter:

Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor  
Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove Campus
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois

Follow along with the slides at:
https://bit.ly/3DusMQk

See the entire program at:
https://bit.ly/2TXTYWx

In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:

• A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
• Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
• Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
• Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
• Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
• The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients

Presenter:

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Link to full program:
https://bit.ly/3BCHF2E